Exact Sciences stock is hot, 'The Street' says

Anticipating strong quarterly earnings for Exact Sciences, TheStreet believes the Cologuard-maker is in line for growth.

Here's what you should know:

1. Exact reports its earnings Aug. 1.

2. The company's stock has jumped 23 percent since the start of the year.

3. Six analysts have awarded Exact a "buy" rating.

4. Baird's Catherine Schulte said, "We believe [Exact] is positioned to deliver on/exceed its 2018 guidance, with marketing campaigns, salesforce expansion and health system penetration all potentially helping [the second half] and beyond." She also predicted Exact will hit around $1 billion in revenues in two years.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast